Background

Hematopoietic stem cells (HSCs) acquire genetic mutations as they age. The phenomenon where specific mutated cell populations expand abnormally to increase their share within the blood is called clonal hematopoiesis (CH). Persistent chronic inflammatory responses in the body increase the fitness of mutated cells compared to normal cells, accelerating the expansion of abnormal clones. Myeloproliferative neoplasms (MPNs), such as myelofibrosis or polycythemia vera, are also deeply intertwined with this chronic inflammatory environment.

This presents a long-standing mystery in the academic community. Interferon-alpha (IFNα), a representative inflammatory cytokine, is a key mediator of inflammatory signals. However, in clinical practice, IFNα is used as a powerful therapeutic agent to deplete mutated hematopoietic stem cell clones in MPN patients. If an inflammatory environment promotes the expansion of mutated cells, why does the administration of the inflammatory molecule IFNα instead suppress tumor clones and sometimes lead to long-term remission? Previous molecular biology studies have remained limited to fragmented explanations, such as the notion that IFNα forces quiescent stem cells into the cell cycle, thereby inducing DNA damage and cell death. This explanation alone made it difficult to clarify why clones completely disappear in some patients while others exhibit resistance and persist under the same drug.

Key Findings

By combining single-cell transcriptomic analysis with tracking models, researchers tracked the behavior of MPN mutated clones stimulated by IFNα over time. The analysis revealed that IFNα signaling does not induce a single cell death pathway. Instead, it was discovered that two conflicting differentiation trajectories competing within the cells are simultaneously promoted.

The first is the clone depletion trajectory. Stem cells receiving strong IFNα stimulation enter a stage of rapid proliferation stress and excessive reactive oxygen species (ROS) accumulation. Mutated cells entering this pathway lose their self-renewal capacity and rapidly transition toward premature differentiation or cell death.

The second pathway is the clone persistence trajectory. Some mutated cells activate a defense mechanism by readjusting stress response gene expression to transition into a metabolically dormant state from the early stages of IFNα exposure. These cells survive while maintaining their inherent stemness despite inflammatory stimuli, serving as seeds that proliferate again when drug administration is discontinued.

Researchers demonstrated that the ultimate fate of a mutant clone is determined not by a single molecular switch, but by the proportion of cells dividing into two lineages and the resulting dynamic equilibrium. Analysis of specimens derived from patients with the JAK2 V617F mutation also showed that the proportion entering the depletion pathway varied depending on the concentration and duration of IFNα exposure. They identified that the initial signal intensity must exceed a specific threshold to block the bypass into the persister pathway and induce permanent depletion of the entire clone.

Implications and Outlook

This discovery suggests that IFNα administration strategies in the treatment of myeloproliferative neoplasms must be completely re-examined. In clinical practice, a low-dose, long-term administration method has commonly been chosen to reduce side effects. However, it has been confirmed that chronic low-dose exposure fails to push cells into the depletion pathway and instead leads them down the persistence trajectory, risking the survival of drug-resistant clones.

Future research is expected to focus on identifying combination targets that block the residual pathway. Inhibiting the metabolic pathways or epigenetic regulators that cells rely on when transitioning to a stress-defense state could maximize the shift toward the exhaustion trajectory during IFNα administration.

Challenges to be addressed are also clear. Indiscriminately increasing the dose of IFNα leads to intolerable toxicities for patients, such as myelosuppression, depression, and systemic inflammatory responses. Developing targeted delivery technologies that can deliver signals above the depletion threshold specifically to mutated hematopoietic stem cells, while avoiding systemic side effects, is the key to clinical success.